(Q39229999)

English

Results of platinum-based chemotherapy in unselected performance status (PS) 2 patients with advanced non-small cell lung cancer: a cohort study

scientific article published on 28 March 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Results of platinum-based chemotherapy in unselected performance status (PS) 2 patients with advanced non-small cell lung cancer: a cohort study (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1 reference

based on heuristic

inferred from title

Florence Canouï-Poitrine

2

object named as

Florence Canoui-Poitrine

0 references

Sylvie Bastuji-Garin

4

object named as

Sylvie Bastuji-Garin

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

author name string

Stéphane Jouveshomme

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Florence Canoui-Poitrine

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Aurélie Le Thuaut

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

publication date

28 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

544

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Treatment of performance status 2 patients with advanced non-small-cell lung cancer: what we know and what we don't know

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Phase II trial of single-agent oral vinorelbine in elderly (> or =70 years) patients with advanced non-small-cell lung cancer and poor performance status

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Impact of referral patterns on the use of chemotherapy for lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: is there a role for targeted therapy in these cohorts?

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0544-5

21 January 2018

Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23535999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23535999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy improves low performance status lung cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23535999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23535999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23535999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23535999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23535999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of poor performance status in lung cancer patients: implications for research

1 reference

https://pubmed.ncbi.nlm.nih.gov/23535999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of two platinum combinations in patients with advanced non-small cell lung cancer: a preliminary report. European Organization for the Research and Treatment of Cancer--Lung Cancer Working Party

1 reference

https://pubmed.ncbi.nlm.nih.gov/23535999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23535999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-013-0544-5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39229999&oldid=2202704717"